UK Markets closed

Hyloris Pharmaceuticals SA (0AB6.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
13.70+0.10 (+0.74%)
At close: 09:45AM BST
Full screen
Previous close13.60
Open13.70
Bid0.00 x N/A
Ask0.00 x N/A
Day's range13.70 - 13.70
52-week range13.56 - 17.14
Volume2
Avg. volume12
Market capN/A
Beta (5Y monthly)0.60
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Hyloris Pharmaceuticals Reports 2022 Half-Year Results and Provides Corporate Update

    - On track to broaden product pipeline to meet a target portfolio of 30 programs by 2024- Continued commercial rollout of Sotalol IV in US and Maxigesic® IV - Focused entry into US market with Maxigesic® IV for non-opioid pain treatment; continuing to work with the FDA to support the application review - Positive clinical data reported for Tranexamic Acid Oral Mouth rinse program (HY-004), for patients on anti-coagulant therapies undergoing dental procedures that have a risk of bleeding complica

  • Globe Newswire

    Hyloris Reports Positive Phase 1 Data for HY-004, a proprietary Tranexamic Acid Oral Mouth Rinse for bleeding related to dental procedures

    Hyloris Reports Positive Phase 1 Data for HY-004, a proprietary Tranexamic Acid Oral Mouth Rinse for bleeding related to dental procedures HY-004 provides a new treatment alternative for use in patients on anti-coagulant therapies undergoing dental procedures that have a risk of bleeding or complicationHY-004 administered locally had minimal systemic exposure and was well-tolerated following molar extraction in healthy patientsHY-004 to be developed to address a significantly larger target marke

  • Globe Newswire

    Hyloris Provides Additional Information on U.S. FDA Review of NDA Application for the Registration of Maxigesic IV®

    FDA did not report any issues with clinical dataHyloris is asked to submit a report describing potential extractable and leachable compounds expected to be present in the drug product based on the drug product packagingHyloris is confident that it can deliver the requested information to FDAHyloris is committed bringing Maxigesic IV to patients in the U.S. as soon as possible and continues to work with the FDA to support the application review Liège, Belgium - 01 July 2022 – 8.00 PM CET - Regula